Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tlr4 polyclonal antibody
- Development stage
- Preclinical
- Lead developer
- Montefiore Einstein Comprehensive Cancer Center
- Modality
- Antibody-Based Therapeutics
- Administration
- Intraperitoneal
01
Overview
The tlr4 polyclonal antibody is a rabbit-derived neutralizing antibody targeting Toll-like receptor 4 (TLR4). It was developed to address the aberrant overactivation of TLR pathways observed in hematopoietic stem cells of patients with Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). By neutralizing TLR4 function, the antibody inhibits downstream signaling pathways, including lipopolysaccharide (LPS)-induced NF-κB activation and the phosphorylation of extracellular signal-regulated kinase (ERK) mitogen-activated protein (MAP) kinase. Preclinical studies using MDS and AML patient samples have demonstrated that treatment with this antibody promotes erythroid and myeloid differentiation, potentially relieving the differentiation block characteristic of these diseases.
- Other names
- anti-TLR4 polyclonal antibodyanti-TLR-4 polyclonal antibodyanti-TLR 4 polyclonal antibody
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on tlr4 polyclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tlr4 polyclonal antibody.